Our Distinctive Approach to Genetic Diseases

Our Focus

Castle Creek Biosciences, Inc., a late-stage cell and gene therapy company, is using lentiviral vector delivery platforms to develop and commercialize gene therapies, initially targeting skin, connective tissue and metabolic diseases. Our scientists use ex vivo and in vivo technologies to switch gene targets and create optimal therapies for a multitude of genetic diseases.

Our Mission

To leverage the science behind our lentiviral vector delivery platforms with our manufacturing experience to create transformative therapies for a broad range of genetic diseases.

Our Commitment to Life Science Innovation

Castle Creek Biosciences is a portfolio company of Paragon Biosciences.

Paragon is a global life science leader that creates, builds and funds innovative biology-based companies in three key areas: cell and gene therapy, adaptive biology and advanced biotechnology. Our portfolio companies use biology to accelerate scientific breakthroughs that solve some of society’s most challenging problems. Committed to this goal, Paragon and its partners have invested more than $1.4 billion since 2017. 

Our Inspiration

We are inspired by people who are impacted by genetic diseases with limited or no therapeutic options.  Our current focus is on dystrophic epidermolysis bullosa (DEB) and hereditary tyrosinemia type 1 (HT1), classical Ehlers-Danlos syndrome (cEDS), and osteogenesis imperfecta (OI), with the goal of expanding our platform to other therapeutic areas, including inborn errors of metabolism.